Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorFoerster, John
dc.contributor.authorBoswell, Kirsty
dc.contributor.authorWest, Jonathan
dc.contributor.authorCameron, Heather
dc.contributor.authorFleming, Colin
dc.contributor.authorIbbotson, Sally
dc.contributor.authorDawe, Robert
dc.date.accessioned2019-08-13T12:30:01Z
dc.date.available2019-08-13T12:30:01Z
dc.date.issued2017-08-03
dc.identifier260534268
dc.identifier0b5e4956-848d-4924-9b46-82bfa2451e33
dc.identifier28771503
dc.identifier85026772325
dc.identifier.citationFoerster , J , Boswell , K , West , J , Cameron , H , Fleming , C , Ibbotson , S & Dawe , R 2017 , ' Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice ' , PLoS ONE , vol. 12 , no. 8 , e0181813 . https://doi.org/10.1371/journal.pone.0181813en
dc.identifier.issn1932-6203
dc.identifier.otherPubMedCentral: PMC5542593
dc.identifier.urihttps://hdl.handle.net/10023/18304
dc.description.abstractBACKGROUND: Narrowband NB-UVB phototherapy (NB-UVB) is an effective treatment for psoriasis, as demonstrated by clinical trials. However, due to required infrastructure and need for treatment attendance opinions on the value of offering this treatment in routine practice vary. AIMS: To provide high quality large-scale and long-term data on the efficacy of NB-UVB for psoriasis under real-world conditions in order to assist in management decisions. METHODS: The following resources were employed: (1) complete and prospectively recorded prescription drug records for a population of 420,000 marked by low demographic mobility, (2) prospectively recorded clinical treatment outcomes for all NB-UVB treatment episodes occurring in the local population; (3) complete dermatology electronic treatment records of all psoriasis patients, allowing cross-validation of diagnoses and treatment records. Using these data sets, we analysed all first-ever initial NB-UVB treatment episodes occurring over 79 months (n = 1749) for both clinical outcomes and the effect of NB-UVB on the use of topical treatments for psoriasis. RESULTS: Around 75% of patients both achieved a status of "clear/minimal disease" and used fewer topical treatments. NB-UVB treatment led to a strong reduction for both steroid creams (25%) and psoriasis-specific topicals, e.g. vitamin-D products (30%) during the 12-month period following NB-UVB treatment. The effects measured were specific as no effect of NB-UVB was noted on drug prescriptions unrelated to psoriasis. Results were independent of individuals administering and/or scoring treatment, as they were highly similar between four geographically separate locations. CONCLUSIONS: NB-UVB treatment is highly effective and leads to a remarkable reduction in the need for topical cream treatments for a period of at least 12 months.
dc.format.extent14
dc.format.extent3040715
dc.language.isoeng
dc.relation.ispartofPLoS ONEen
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectChilden
dc.subjectChild, Preschoolen
dc.subjectDrug Prescriptionsen
dc.subjectRL Dermatologyen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectNDASen
dc.subject.lccRLen
dc.subject.lccRMen
dc.titleNarrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practiceen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doi10.1371/journal.pone.0181813
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record